Group 1: Company Performance and Market Trends - 和誉-B (2256.HK) has a total market value of HKD 76 million, with a current price of HKD 11.15, showing a price increase of 158.7% since its inclusion on November 1, 2024[3] - 基石药业-B (2616.HK) has a market value of HKD 92 million, with a current price of HKD 6.26, reflecting a price drop of 24.7% since February 2, 2026[3] - 宜明昂科-B (1541.HK) has a market value of HKD 15 million, with a current price of HKD 3.55, down 48.6% since April 2, 2025[3] - 石药集团 (1093.HK) has a market value of HKD 1,062 million, with a current price of HKD 9.22, showing a slight increase of 3.0% since September 26, 2025[3] Group 2: Financial Metrics and Projections - 和誉-B (2256.HK) has an EPS of HKD 0.04 for 2024, with a PE ratio of 258.13 and a PB ratio of 3.59[3] - 基石药业-B (2616.HK) has an EPS of -0.07 for 2024, with a PE ratio of -89.43 and a PB ratio of 23.52[3] - 宜明昂科-B (1541.HK) has an EPS of -0.91 for 2024, with a PE ratio of -3.91 and a PB ratio of 2.09[3] - 石药集团 (1093.HK) has an EPS of 0.40 for 2024, with a PE ratio of 23.16 and a PB ratio of 3.05[3] Group 3: Strategic Insights - 和誉-B has a strong pipeline of 16 oncology drug candidates, with 10 in clinical stages, and a licensing agreement with Merck worth USD 605.5 million[3] - 基石药业-B has successfully launched 4 innovative drugs and is conducting global clinical trials for its core product CS2009, a tri-specific antibody[3] - 宜明昂科-B's core product IMM01 is the first SIRPα-Fc fusion protein in clinical stages in China, with promising clinical data and a rich pipeline[3] - 石药集团 is focusing on oncology, neuropsychiatric, and cardiovascular treatments, with over 60 key drugs in clinical or application stages, expecting a recovery in performance post-2025[3]